ACTRN12620001019998
Completed
Phase 1
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor Antagonist in healthy adults
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Hepatitis B
- Sponsor
- Gilead Sciences
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Screening laboratory evaluations and 12\-lead ECG evaluations must be without clinically
- •significant abnormalities as assessed by the investigator
- •\- Must, in the opinion of the investigator, be in good health based upon medical history and
- •physical examination, including vital signs
Exclusion Criteria
- •\- Pregnant or Breastfeeding
- •\- Have received any study drug within 30 days prior to study dosing
- •\- Have poor venous access that limits phlebotomy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteersAcromegalyNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)ACTRN12620001261909Ascil Australia Pty LTD16
Completed
Phase 1
A First-in-Human Study of a new Controlled Release Formulation of Octreotide acetate in healthy male volunteersAcromegalyNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)ACTRN12620000108910Ascil Australia Pty Ltd8
Recruiting
Phase 1
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.CTIS2023-503948-13-00aboratorios Farmaceuticos Rovi S.A.90
Completed
Phase 1
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesIdiopathic Pulmonary FibrosisRespiratory - Other respiratory disorders / diseasesACTRN12620001141932Avalyn Pharma Pty Ltd38
Active, not recruiting
Not Applicable
Safety and Tolerability of Ceftazidime-Avibactam for pediatric patients with suspected or confirmed infectionshospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection.MedDRA version: 14.1Level: LLTClassification code 10021804Term: Infection bacterialSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2013-001900-13-Outside-EU/EEAAstraZeneca AB32